Takeki Suzuki

Cardiac electrophysiologist. Views are my own. #Fluoroless #Zerofluoro #Afib

[Parag Chevli MD MS @paragchevli]

1/4 🫀📢 Our MESA study is out! Can ketone bodies, NT-proBNP, and hs-cTnT together help characterize future atrial fibrillation (AF) risk? A short thread 🧵👇
Read the paper: https://t.co/csKeBf8fgP

[NEJM @NEJM]

Original Article: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF trial) https://t.co/fsN8QZhgYh

Editorial: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke https://t.co/RX8U46dRZb

#Cardiology #ESCCongress

[Takeki Suzuki @takekisuzuki]

@johnkioka すごい病院ですね😃私が研修した病院も結構すごかったですし、以前働いた病院のERもそんな雰囲気がありましたが、それらとは比べ物にならなそうです！

[NEJM @NEJM]

Original Article: Anticoagulation for Atrial Fibrillation with Intermediate Stroke Risk (SINGLE-AF trial) https://t.co/fsN8QZhgYh

Editorial: Anticoagulation for Atrial Fibrillation with a Single Risk Factor for Stroke https://t.co/RX8U46dRZb

#ESCCongress | @escardio

[JAMA @JAMA_current]

Presented at #ESCCongress:

Among patients with symptomatic persistent #AtrialFibrillation, adding posterior wall isolation to pulsed field ablation-based pulmonary vein isolation did not significantly reduce recurrence of atrial tachyarrhythmia compared with pulmonary vein isolation alone.

Continuous implantable cardiac monitor follow-up showed recurrence in about half of patients receiving posterior wall isolation and in more than half receiving pulmonary vein isolation alone.

🔗 https://t.co/AV5aSLYDJY

[Takeki Suzuki @takekisuzuki]

@GenShinozakiMD お疲れ様でした！新天地でのご活躍をお祈りしております！

[Jameis Winston @Jaboowins]

Thank you and all the Japanese supporters for sharing your traditions with me! 🇯🇵

This World Cup is all about spreading culture and miracles 🙌🌎 #JameisOnFox

[Takeki Suzuki @takekisuzuki]

@GenShinozakiMD 異動ご決定おめでとうございます！益々のご活躍を！

[Takeki Suzuki @takekisuzuki]

@johnkioka Dr. Yasu Okaも載ってますね！

[Takeki Suzuki @takekisuzuki]

Heart Rhythm Society and Milestone Pharmaceuticals Partner to Expand SVT Patient Education Through https://t.co/qh4Pdg9r5H - HRS https://t.co/TDn5Y2nCrO

[EHJ Editor-in-Chief @ehj_ed]

Discontinuation of digoxin after long-term treatment is associated with clinical deterioration in patients with HF and a reduced or mildly reduced ejection fraction. Read the results of the DECISION trial just published in #EHJ and presented at ESC Heart Failure Congress 2026

https://t.co/dO805FqWsh
@escardio @ESC_Journals #FastTrackCongress #HFA2026 #ESCHeartFailure2026

[Takeki Suzuki @takekisuzuki]

Glucagon-like peptide-1 and atrial fibrillation incidence: Associations independent of weight loss - Heart Rhythm https://t.co/lzFG69r8mx

[Takeki Suzuki @takekisuzuki]

@rblument1 @DrMichaelShapir Congratulations, @DrMichaelShapir !

[Roger Blumenthal @rblument1]

Congrats to @DrMichaelShapir on this great honor. Dr. Shapiro has done a marvelous job as President of ASPC and was a key member of the writing group of the practice-changing 2026 ACC/AHA/Multisociety Dyslipidemia Guideline. Congratulations, Michael on the Arthur Agatston award!

[NEJM @NEJM]

Presented at #HRS2026:

In patients with persistent atrial fibrillation, first-line treatment with pulsed field ablation reduced the recurrence of atrial arrhythmias at 12 months as compared with antiarrhythmic drugs. Full AVANT GUARD trial results: https://t.co/milHy26ojJ

@HRSonline

[Takeki Suzuki @takekisuzuki]

Great keynote presentation by @DGlaucomflecken @HRSonline

[American Heart Association @American_Heart]

The American Heart Association mourns the passing of the legendary cardiologist Eugene Braunwald, M.D., widely recognized as one of the most influential figures in the history of cardiovascular medicine. Over seven decades, his work reshaped the understanding and treatment of heart disease, leading many to call him the father of modern cardiology.

Braunwald was a lifelong contributor to the American Heart Association, helping advance its research and scientific mission, and was honored with some of the Association’s highest honors for his lasting influence on cardiovascular care and research. His influence extended well beyond his own discoveries, as generations of Association‑supported investigators, clinicians and academic leaders were trained by Braunwald or guided by the clinical trial standards and mentorship models he helped establish.

https://t.co/ieZuHYMyOP

[NASA @NASA]

Liftoff.

The Artemis II mission launched from @NASAKennedy at 6:35pm ET (2235 UTC), propelling four astronauts on a journey around the Moon.

Artemis II will pave the way for future Moon landings, as well as the next giant leap — astronauts on Mars.

[NEJM @NEJM]

Presented at #ACC26:

In patients with atrial fibrillation, left atrial appendage closure was noninferior to NOACs in an analysis of death from cardiovascular causes, stroke, or systemic embolism and was superior for non–procedure-related bleeding. Full CHAMPION-AF trial results: https://t.co/5Uv4N1HXXn

Editorial: Left Atrial Appendage Closure — Should Recommendations Be Expanded? https://t.co/afTN59ySIA

@ACCinTouch

[NEJM @NEJM]

Among patients with atrial fibrillation at high risk for stroke and bleeding, left atrial appendage closure was not noninferior to medical therapy in reducing the risk of stroke, embolism, major bleeding, or death at 3 years. Full CLOSURE-AF trial results: https://t.co/qAMC2o36Mi

Editorial: Left Atrial Appendage Closure — Another Overused Method in Cardiology? https://t.co/KyOWdblUR3